No Data
Fuyuan Pharmaceutical (601089.SH): Erythromycin ophthalmic ointment has obtained the approval notification for the supplementary Pharmaceutical application.
On January 7, Gelonghui reported that Fuyuan Pharmaceuticals (601089.SH) announced that its wholly-owned subsidiary, Fuyuan Pharmaceutical Co., Ltd., has obtained the "Approval Notification for Pharmaceutical Supplement Application" for "Erythromycin Eye Ointment" issued by the National Medical Products Administration. The marketing authorization holder for the pharmaceutical has been changed from Xi'an Kanghua Pharmaceutical Co., Ltd. to Fuyuan Pharmaceutical Co., Ltd. This pharmaceutical is mainly used for trachoma, conjunctivitis, blepharitis, and external eye infections.
Fuyuan Pharmaceutical (601089.SH): Received the approval notification for the listing application of Chemical Raw Materials.
Gelonghui, December 16 - Fuyuan Pharmaceutical (601089.SH) announced that the company received the "Approval Notification for the Listing Application of Active Pharmaceutical Ingredient Dapagliflozin" issued by the National Medical Products Administration. Dapagliflozin is used for the treatment of adult patients with type 2 diabetes.
Fuyuan Pharmaceutical (601089.SH): Participating in the tenth batch of national Pharmaceutical centralized procurement is expected to be selected.
On December 13, Gelonghui reported that Fuyuan Pharmaceutical (601089.SH) announced that on December 12, 2024, the company participated in the bidding work for the tenth batch of national centralized pharmaceutical procurement organized by the National Joint Procurement Office (hereinafter referred to as "Joint Procurement Office"). After opening and evaluating the bids by the Joint Procurement Office, the company's product, azilsartan and hydrochlorothiazide tablets, is expected to win the bid for this centralized procurement. The selection of supply provinces for azilsartan and hydrochlorothiazide tablets has been based on market potential in each province, and the results will be officially released after being announced by the Joint Procurement Office.
Fufeng Pharmaceutical (601089.SH): Montmorillonite powder obtained pharmaceutical registration certificate.
Fuyuan Pharmaceutical (601089.SH) announced that recently, its wholly-owned subsidiary zhejiang Aisheng Pharmaceutical Co., Ltd. (...)
Fuyuan Pharmaceutical (601089.SH): Maoguoyunxiang alkaloid hydrochloride eye drops obtained the Notice of Approval for Clinical Trials of Drugs.
Fufeng Pharmaceutical (601089.SH) announced that the company recently received the approval and issuance of the National Medical Products Administration...
Beijing Fuyuan Pharmaceutical Co., Ltd. Report for the third quarter of 2024
No Data
